News

Late-breaking EADV 2026 data showed significant improvements in skin clearance, itch, pain, and patient satisfaction among patients treated with lebrikizumab.

Day 1 of EADV 2026 brought new data across atopic dermatitis, cutaneous lupus, skin cancer, AI, climate-related skin disease, and more.

On this episode of Don't Be Rash, Andrew Krakowski, MD, spoke with Sheilagh Maguiness, MD, about the FDA's approval of bemotrizinol and what the new sunscreen filter means for pediatric patients.

Up to 91% of patients reached EASI-75 and up to 67% reached IGA 0/1 at week 152, with no new safety signals, according to Galderma's EADV 2026 data.

Two studies presented at EADV 2026 highlight misinformation and dermatologic complications linked to viral skincare routines on social media.

Phase 2 data presented at EADV 2026 showed daxdilimab significantly reduced disease activity and improved response rates in treatment-refractory DLE.

Presented as a late breaker at EADV 2026, mid-dose zumilokibart achieved EASI-75 in 65.9% of adults with atopic dermatitis vs 23.4% with placebo at week 16.

This review of the latest dermatological studies includes insights on ruxolitinib for lichen planus, early vitiligo treatment, psoriasis response, AD disease control, and PFB management.

EADV 2026 data highlight dupilumab’s effects on growth, quality of life, disease control, and itch across multiple dermatologic diseases.

The FDA approved therapies for melanoma, dermatomyositis, superficial basal cell carcinoma, and adolescent alopecia areata, while TYK2 inhibitors and rare disease filings advanced toward 2027 decisions.

Dermatology Times is looking back on the top stories in dermatology from the month of September.

Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.

From emerging therapies to earlier intervention and psychosocial support, Dermatology Times looks back at key alopecia areata developments in 2026.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.

The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.

Explore what drives male pattern hair loss, its emotional toll, and why new topical antiandrogen clascoterone may boost density while limiting systemic effects.

Guselkumab met primary and major secondary endpoints in the phase 4 STAR study, improving axial PsA symptoms and MRI-confirmed inflammation.

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of September.

Three experimental hair loss mechanisms are moving through late-stage trials for the first time in decades, and the data are worth knowing before patients ask.

Alexandra Charrow, MD, discussed biologic selection, deroofing, and emerging procedural approaches to hidradenitis suppurativa at Maui Derm NP+PA Fall 2026.

Week 28 data from the phase 2a EVERLAST-A trial showed PASI 100 responses increased to 71.4% despite no additional ORKA-001 dosing after week 4.

Immunovant will discontinue development of imeroprubart in cutaneous lupus erythematosus after the phase 2b study failed to meet its primary endpoint.

This review of the latest dermatological studies includes insights on artificial intelligence, interstitial granulomatous dermatitis and atopic dermatitis

On this episode of Don't Be Rash, Lisa Swanson, MD, joined host Andrew C. Krakowski, MD, to walk through the pediatric psoriasis treatment ladder, from first-line topicals to biologics and a new oral IL-23 blocker.

For Alopecia Awareness Month, Deann of Alopecia Life discusses compassion, treatment expectations, and the psychosocial burden of alopecia areata.

Both barzolvolimab doses improved UAS7 at week 12 in EMBARQ-CSU1 and EMBARQ-CSU2, with up to 54% of patients reaching complete response by week 24.

The designation marks the first FDA Fast Track status granted to a therapy for peeling skin syndrome, which currently has no approved treatment.

The merger, backed by an oversubscribed $180 million private placement, will fund development of NOR-101, an IL-13 x IL-18 bispecific antibody entering phase 1 trials in atopic dermatitis in early 2027.

Maui Derm NP+PA Fall 2026 brought APPs together for updates spanning inflammatory disease, oncology, emerging therapies, and diagnostic challenges.